Innoviva - 21 Year Stock Split History | INVA

Stock split history for Innoviva since 2004. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Innoviva Annual Stock Splits
Innoviva Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.145B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $796.425B 64.61
Johnson & Johnson (JNJ) United States $379.479B 15.67
AbbVie (ABBV) United States $306.016B 17.09
Novo Nordisk (NVO) Denmark $260.636B 17.65
Roche Holding AG (RHHBY) Switzerland $248.102B 0.00
Novartis AG (NVS) Switzerland $234.183B 14.19
Merck (MRK) United States $196.697B 10.21
Sanofi (SNY) France $128.587B 12.24
Pfizer (PFE) United States $125.566B 7.12
Bayer (BAYRY) Germany $23.657B 4.39